Anti-integrin antibodies, compositions, methods and uses

Details Anti-integrin antibodies, compositions, methods and uses Anti-integrin antibodies, compositions, methods and uses

2007-01-16

2007-01-16

Haddad, Maher M. (Department: 1644)

Drug, bio-affecting and body treating compositions

Immunoglobulin, antiserum, antibody, or antibody fragment,...

Monoclonal antibody or fragment thereof

C530S388150, C530S388220

Reexamination Certificate

active

10720323

ABSTRACT:
The present invention relates to at least one novel anti-alpha-V subunit antibodies, including isolated nucleic acids that encode at least one anti-alpha-V subunit antibody, alpha-V subunit, vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including therapeutic compositions, methods and devices.

REFERENCES:
patent: 5674483 (1997-10-01), Tu et al.
patent: 5753230 (1998-05-01), Brooks et al.
patent: 5877397 (1999-03-01), Lonberg et al.
patent: 5985278 (1999-11-01), Mitjans et al.
patent: 6171588 (2001-01-01), Carron et al.
patent: 6342221 (2002-01-01), Thorpe et al.
patent: 6359126 (2002-03-01), Kim et al.
patent: 6369204 (2002-04-01), Kim et al.
patent: 6632927 (2003-10-01), Adair et al.
patent: 2001/0011125 (2001-08-01), Huse
patent: 2003/0143603 (2003-07-01), Giles-Komar et al.
patent: 0 260 829 (1988-03-01), None
patent: 719859 (1996-07-01), None
patent: 0 834 557 (1998-04-01), None
patent: WO 93/20229 (1993-10-01), None
patent: WO 94/12181 (1994-06-01), None
patent: WO 95/25543 (1995-09-01), None
patent: WO 97/06791 (1997-02-01), None
patent: WO 97/36859 (1997-10-01), None
patent: WO 0031248 (2000-06-01), None
patent: WO 0044404 (2000-08-01), None
Rudikoff et al Single amino acid substitution altering antigen-binding specificity. Proc Natl Acad Sci U S A. Mar. 1982;79(6):1979-83.
Panka et al. Variable region framework differences result in decreased or increased affinity of variant anti-digoxin antibodies. Proc Natl Acad Sci U S A. 85(9):3080-3084, 1988.
Amit et al., Three-dimensional structure of an antigen-antibody complex at 2.8 A resolution. Science. 233(4765):747-753, 1986.
Wayner et al Integrins alpha v beta 3 and alpha v beta 5 contribute to cell attachment to vitronectin but differentially distribute on the cell surface. J Cell Biol. May 1991;113(4):919-29.
Chemicon International catalog No. MAB1953Z, p. 1, Jan. 27, 2006.
Tam et al, “Abciximab (ReoPro, Chimeric 7E3 Fab) Demonstrates equivalent affinity and functional blockade of glycoprotein lib/llla and αvβ3Integrins,” vol. 98, No. 11, Sep. 15, 1998, pp. 1098-1091, USA.
Trikha et al, “A potential new application for a cardiovascular drug: Role for ReoPro (Abciximab), an inhibitor of GBllB/lllA and alphaVbeta3 integrins, as an anti-cancer agent,” Proceedings of the American Association for Cancer Research, vol. 41, Mar. 2000, p. 577, USA.
Suzuki et al, “cDNA and amino acid sequences of the cell adhesion protein receptor recognizing vitronectin reveal a transmembrane domain and homologies with other adhesion protein receptors,” Cell Biology, Nov. 1986, pp. 8614-8618, vol. 83, Proc. National Academy Science, USA.
Lehmann et al, “A monoclonal antibody inhibits adhesion to fibronectin and bitronectin of a colon carcinoma cell line and recognizes the integrins ανβ3,ανβ5, ανβ6,” Cancer Research, 1994, pp. 2102-2107, vol. 52 USA.
Gunther Castl, Thomas Hermann, Mciahel, Steurer, Jorg Zmija, Eberhard Gunsilius, Clemens Unger, and Andrea Kraft, “Angiogenesis as a target for tumor treatment,” Oncology, 1997, 177-84, vol. 54.
Brian P. Eliceiri and David A. Cheresh, “The role of alpha-v integrins during angiogenesis: insights into potential mechanisms of action and clinical development,” The Journal of Clinical Investigation, May 1999, 1227-30, vol. 103, No. 9.
Martin Friedlander, Peter C. Brooks, Robert W. Shaffer, Christine M. Kincaid, Judith A. Varner, and David A. Cheresh, “Definition of Two Angiogenic Pathways by Distinct Alpha-V Integrins,” Science, Dec. 1, 1995, 1500-2, vol. 270.
Lisa D. Taylor, Condie E. Carmack, Dennis Huszar, Kay M.Higgins, Roshanak Mashayekh, Getachew Sequar, Stephen R. Schramm, Chiung-Chi Kuo, Susan L. O'Donnell, Robert M. Kay, Olive S. Woodhouse, and Nils Lonberg, “Human immunoglobulin transgenes undergo rearrangement , somatic mutuation and class switching in mice that lack endogenous lgM,” International Immunology, 1994; 579-91, vol. 6 No. 4, Oxford University Press.
Nils Lonberg, Lisa D. Taylor, Fiona A. Harding, Mary Trounstine, Kay M. Higgins, Stephen R. Schramm, Chiung-Chi Kuo, Roshanak Mashayekh, Kathryn Wymore, James G. McCabe, Donna Munoz-O'Regan, Susan L. O'Donnell, Elizabeth S. G. Lapachet, Tash Bengoechea, Diane M. Fishwild, Condie E. Carmack, Robert M. Kay and Dennis Huszar, “Antigen-specific human antibodies from mich comprising four distinct genetic modifications,” Nature, Apr. 28, 1994, 856-9, vol. 368.
Michael Neuberger, “Generating high-avidity human Mabs in mice,” Nature Biotechnology, Jul. 1996, 826, vol. 14.
Dianne M. Fishwild, Susan L. O'Donnell, Tash Bengoechea, Debra V. Hudson, Fiona Harding, Susan L. Bernhard, Debbie Jones, Robert M. Kay, Kay M. Higgins, Stephen R. Schramm, and Nils Lonberg, “High-avidity human IgG-kappa monoclonal antibodies from a novel strain of minilocus transgenic mice,” Nature Biotechnology, Jul. 1996, 845-51, vol. 14.
Elizabeth A. Wayner, Robert A. Orlando and David A. Cheresh, “Integrins alpha v beta 3 and alpha v beta 5. Contribute to Cell Attachement to Vitronectin but Differentially Distribute on the Cell Surface,” J. Cell Biology, May 1991, 919-29, vol. 113, No. 4.
John F. Marshall, Deborah C. Rutherford, Alison C.E. McCartney, Francesc Mitjans, Simon L. Goodman and Ian R. Hart, “Alpha v beta 1 is a receptor for vitronectin and fibriogen, and acts with alpha 5 beta 1 to mediate spreading on fibronectin,” J. of Cell Science, 1995, 1227-38, vol. 108.
David A. Cheresh and Robert C. Spiro, “Biosynthetic and Functional Properties of an Arg-Gly-Asp-directed Receptor involved in Human Melanoma Cell Attachment to Vitronectin, Fibrinogen, and von Willebrand Factor,” J. of Biological Chemistry, Dec. 25, 1987, 17703-11, vol. 262, No. 36.
Hans Kemperman, Yvonne M. Wijnands, and Ed Roos, “Alpha v Integrins on HT-29 Colon Carcinoma Cells: Adhesion to Fibronectin in Mediated Solely by Small Amounts of alpha v beta 6, and alpha v beta 5 is Codistributed with Actin Fibers,” Experimental Cell Research, 1997, 156-64, vol. 234.
J. Orihara, “Sensitizing Capacity, Cross-Reactivity and Antigenic Determinants of Bisphenol A”, The Journal of Stomatological Society, vol. 59, No. 2, Jun. 1992, pp. 439-455, English Abstract only.
M. Castillo et al., “Analysis of Industrial Effluents to Determine Endocrine-Disrupting Chemicals”, Trends in Analytical Chemistry, vol. 16, No. 10, Nov. 12, 1997, pp. 574-583.
J. Gascon et al., “Detection of Endocrine-Disrupting Pesticides by Enzyme-Linked Immunosorbent Assay (ELISA): Application to Atrazine”, Trends in Analytical Chemistry, vol. 16, No. 10, 1997, pp. 554-562.
Mitjans et al, “In Vivo Therapy of Malignant Melanoma by Means of Antagonists of αν Integrins,” Int. J. Cancer, 2000, pp. 716-723, vol. 87, Wiley-Liss, Inc., Spain.
Mitjans et al, “An anti-αν-integrin antibody that blocks Integrin function Inhibits the development of a human melanoma in nude mice,” Journal of Cell Science, 1995, pp. 2825-2838, vol. 108, The Company of Biologists Limited, Great Britain.
Casel et al, “RGD Peptides and Monoclonal Antibodies, Antagonists of αν-Integrin, Enter the Cells by Independent Endocytic Pathways,” Laboratory Investigation, 2001, pp. 1615-1626, vol. 81, No. 12, The United States and Canadian Academy of Pathology, Inc, USA.
Mitijans et al, J. Cell Sci, 1995, [pp. 2825-2838, vol. 108.
Lehmann et al, Cancer Res, 1994, pp. 2102-2107, vol. 54.
Friedlander et al, Science, 1995, pp. 1500-1502, vol. 270.
Friedlander et al, Proc Natl Acad Sci, 1996, pp. 9764-9769, vol. 93 USA.

Affiliated with

Also associated with

Rating

Anti-integrin antibodies, compositions, methods and uses does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Anti-integrin antibodies, compositions, methods and uses, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anti-integrin antibodies, compositions, methods and uses will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3824378